GIST News Briefs

social media

Automated Monitoring of Online Forums Could Yield New Insights on Drug Side Effects

Automated monitoring of online patient forums may provide real-world data on adverse drug events (ADEs) and could be used to supplement pharmacovigilance, according to a study of patients with gastrointestinal stromal tumors. The research was published in Scientific Reports. Clinical trials are often relatively short in duration and are conducted in a small sample of…

GIST

TRK Fusions Found in Some GIST Cases Without KIT/PDGFRA Mutations

Some cases of gastrointestinal stromal tumor (GIST) without mutations in the typical KIT or PDGFRA genes (KIT/PDGFRA WT) may contain tropomyosin-related kinase (TRK) fusions, according to a study published in Cancers. A total of 16% of GIST cases (5/31) were found to contain TRK fusions in the neurotrophic tyrosine receptor kinase (NTRK) gene, which encodes…

Laparoscopic surgery

Hand-Assisted Laparoscopic Surgery Benefits Gastric GIST

Shorter operative time, a simpler operation, and faster postoperative recovery time are some of the advantages of hand-assisted laparoscopic surgery (HLS) compared with total laparoscopic surgery (TLS) for the surgical treatment of gastric gastrointestinal stromal tumors (GISTs), according to a retrospective analysis published in BMC Surgery. TLS has replaced open surgery for the treatment of…

orphan drug designation

FDA Grants Orphan Drug Designation to Ilixadencel for GIST

Immunicum AB announced via news release that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to ilixadencel, an off-the-shelf cell-based cancer immunotherapy aimed to treat gastrointestinal stromal tumors (GISTs). “We continue to interact with agencies on the development of treatments for hard-to-treat tumors,” Jeroen Rovers, MD, PhD, chief medical officer of…

doctor and patient

Three Years of Adjuvant Imatinib Tolerable and Effective for GIST, Study Finds

Treatment with adjuvant imatinib for 3 years, which is the current standard of care for patients with high-risk gastrointestinal stromal tumors (GISTs), is generally well-tolerated and effective, according to a new study published in the International Journal of Cancer. This finding is consistent with the clinical outcomes of previous reports. Factors associated with poor recurrence-free…

gastro tumor

Olverembatinib Shows Therapeutic Potential in GIST

Olverembatinib leads to a clinical benefit rate of 83.3% in patients with gastrointestinal stromal tumors (GISTs) who were resistant to or failed prior treatment with tyrosine kinase inhibitors, according to results from a phase 1b/2 clinical trial presented at the 58th American Society of Clinical Oncology (ASCO) Annual Meeting. The open-label, multicenter trial evaluated the…

digital graph

Pimitespib Improves Progression-Free Survival in Advanced GIST Study

Researchers found improved progression-free survival (PFS) with pimitespib compared with placebo in patients with previously treated advanced gastrointestinal stromal tumors (GISTs). The study, published in the Annals of Oncology, also found an acceptable safety profile and a benefit to pimitespib regardless of KIT mutations. “Here, we report the results from the placebo-controlled, phase 3 study…

tissue samples

SMYD2 Accelerates Disease Progression in GIST

Researchers have discovered that SMYD2, an oncogene, aggravates and accelerates gastrointestinal stromal tumors (GISTs), and published their findings in Cell Death Discovery.  Around 1 in 5 patients with GISTs present with metastasis at diagnosis, usually to the liver or throughout the serosa of the abdomen. Studies show that patients with GISTs typically demonstrate high resistance…

gastric cancer

Neoadjuvant Imatinib Useful for Minimally Invasive GIST Resection

Neoadjuvant imatinib can cause significant shrinkage of gastric gastrointestinal stromal tumors (GISTs), thus facilitating the minimally invasive resection of the tumor, according to a study published in Annals of Surgical Oncology. The current treatment for localized GISTs is surgical resection. Studies have validated the use of adjuvant imatinib for patients who are at high risk…

Next post in GIST News Briefs